Trial Profile
An open-label extension study of long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms INPULSIS-ON
- Sponsors Boehringer Ingelheim; Unilfarma
- 24 May 2023 Results (n=418) assessing the associations between HRCT features and FVC % predicted at baseline and time to a composite outcome indicating disease progression from INPULSIS trials, presented at the 119th International Conference of the American Thoracic Society.
- 27 Dec 2021 Results published in the Advances in Therapy
- 12 Feb 2021 Status changed from active, no longer recruiting to completed.